Results 11 to 20 of about 1,655,298 (265)

High dose rate brachytherapy for oral cancer [PDF]

Journal of Radiation Research, 2012
Brachytherapy results in better dose distribution compared with other treatments because of steep dose reduction in the surrounding normal tissues. Excellent local control rates and acceptable side effects have been demonstrated with brachytherapy as a sole treatment modality, a postoperative method, and a method of reirradiation.
YamazakI, Hideya, Yoshida, Ken, Yoshioka, Yasuo, Shimizutani, Kimishige, Furukawa, Souhei, Koizumi, Masahiko, Ogawa, Kazuhiko   +6 more
openaire   +2 more sources

High dose rate brachytherapy

International Journal of Radiation Oncology*Biology*Physics, 1993
The high dose rate brachytherapy uses a single source os 192Ir with 10Ci of nominal activity in a remote afterloading machine. This technique allows an outpatient treatment, without the inconveniences of the conventional low dose rate brachytherapy such as use of general anesthesia, rhachianesthesia, prolonged immobilization, and personal exposition to
S, Aisen, H A, Carvalho, M C, Chavantes, S C, Esteves, C M, Haddad, A C, Permonian, M do C, Taier, R C, Marinheiro, C V, Feriancic   +8 more
openaire   +3 more sources

Modern development of high-dose-rate brachytherapy [PDF]

Japanese Journal of Clinical Oncology, 2020
AbstractBrachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law.
openaire   +2 more sources

Out-patient high-dose-rate endobronchial brachytherapy for palliation of lung cancer: an observational study

Monaldi Archives for Chest Disease, 2016
Background and Aim. Out-patient high-dose-rate endobronchial brachytherapy (HDREB) is a possible option in the palliation of symptoms in patients with advanced lung cancer, but literature data is limited and the technique is still under development in ...
A. Scarda, M. Confalonieri, C. Baghiris, S. Binato, R. Mazzarotto, A. Palamidese, R. Zuin, U. Fantoni   +7 more
doaj   +1 more source

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate

Frontiers in Oncology, 2019
For patients with unfavorable or high-risk prostate cancer, dose escalated radiation therapy leads to improved progression free survival but attempts to deliver increased dose by external beam radiation therapy (EBRT) alone can be limited by late ...
Benjamin W. Fischer-Valuck, Hiram A. Gay, Sagar Patel, Brian C. Baumann, Jeff M. Michalski   +4 more
doaj   +1 more source

Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy

Journal of Contemporary Brachytherapy, 2016
Purpose: To evaluate the feasibility of the use of real-time magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion guided high-dose-rate brachytherapy (HDR-BT) +/– external beam radiation therapy (EBRT) in patients with histologically ...
David Buchser, Alfonso Gomez-Iturriaga, J. Ignacio Rodriguez Melcon, Francisco Casquero, Roberto Llarena, Jon Cacicedo, Pedro Bilbao   +6 more
doaj   +1 more source

Optically stimulated luminescent dosimetry for high dose rate brachytherapy

Frontiers in Oncology, 2012
Purpose: The objective was to determine whether optically stimulated luminescent dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate brachytherapy. In order to make this distinction, three dosimetric characteristics were tested:
Christopher Jason Tien, Robert eEbeling, Jessica R Hiatt, Bruce eCurran, Edward eSternick   +4 more
doaj   +1 more source

Out-of-field dose in stereotactic radiotherapy for paediatric patients

Physics and Imaging in Radiation Oncology, 2021
Background and purpose: Stereotactic radiotherapy combines image guidance and high precision delivery with small fields to deliver high doses per fraction in short treatment courses.
Lachlan Garrett, Nicholas Hardcastle, Adam Yeo, Peta Lonski, Rick Franich, Tomas Kron   +5 more
doaj   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source